Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | KDM5A | P29375 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018995 | 0.80 | KDM5B (0.35) | KDM5BKDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL27311213 | 0.77 | TDP1 (0.49) | KDM5BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7016511 | 0.74 | KDM5B (0.44) | KDM5BKDM5ALMNASMN1; SMN2 | |
| SCHEMBL24097994 | 0.70 | BRD4 (0.33) | — | |
| SCHEMBL31677987 | 0.69 | KDM5B (0.43) | KDM5BKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL31661272 | 0.68 | KMT2A (0.50) | KDM4EALDH1A1HSD17B10LMNACYP1A2 | |
| SCHEMBL8471789 | 0.68 | TDP1 (0.62) | KDM5BKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL6501337 | 0.68 | ENPP2 (0.64) | KDM5BKDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL24236856 | 0.67 | LMNA (0.32) | KDM4EHSD17B10LMNACYP1A2 | |
| SCHEMBL11357153 | 0.67 | KDM4E (0.55) | KDM5BKDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128561-A1 | MRGX Receptor Antagonists | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2021-05-06 | — | — | US | disclosed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-5753664-A | ANTITUMOR AGENTS, PYRIMIDONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128561-A1 | MRGX Receptor Antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | KDM5B 2722/4885KDM4E 3530/4885ALDH1A1 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.